Cancer Survivorship Training Program

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 2
Volume 7
Issue 2

BETHESDA, Md-In response to the difficult and complex issues affecting cancer survivors, the National Cancer Institute (NCI) has created a new training program, The Cancer Journey: Issues for Survivors. It is designed for health professionals in training roles to educate their peers about the many issues cancer survivors face.

BETHESDA, Md—In response to the difficult and complex issues affecting cancer survivors, the National Cancer Institute (NCI) has created a new training program, The Cancer Journey: Issues for Survivors. It is designed for health professionals in training roles to educate their peers about the many issues cancer survivors face.

The training program was developed by NCI’s Office of Cancer Information, Communication, and Education in collaboration with Ortho Biotech Inc., the National Coalition for Cancer Survivorship, and cancer organizations nationwide.

To obtain a free copy of the training program, please contact the NCI’s Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).

Articles in this issue
Tobacco Companies Reach Settlement With Texas for $15.3 Billion
Archives to Collect Info on Radiation Exposure Worldwide
Few BRCA-1 Carriers Take Recommended Precautions
Lifelong Weight Control a Key to Breast Ca Prevention
Eight-Year Prostate Brachytherapy Update Shows Good Results
Patient Brochure on Breast Cancer Tumor Markers
Gay Men’s Health Crisis Calls for HIV Reporting in New York
Single-Agent Taxanes in Advanced Breast Cancer: A Commentary
ODAC Declines to Vote on DepoCyt FDA Recommendation
Photofrin Approved for Early-Stage Lung Cancer
Breast Cancer Diagnosed After Childbirth May Be More Severe
NCCN Forum: Who Pays for Clinical Trials?
AHCPR Smoking Interventions Are Cost Effective
Senator Urges Consensus on Tobacco Law
Thomas Jefferson Opens New Familial Colorectal Cancer Registry

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
4 experts in this video
4 experts in this video
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Related Content
EC Approves T-DXd Monotherapy in HR+, HER2-Low/Ultralow Breast Cancer

EC Approves T-DXd Monotherapy in HR+, HER2-Low/Ultralow Breast Cancer

Tim Cortese
April 4th 2025
Article

Results from the phase 3 DESTINY-Breast06 trial demonstrated that T-DXd monotherapy improved PFS over chemotherapy in patients with breast cancer.

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
April 1st 2025
Podcast

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

All patients identified as low risk for sentinel lymph node positivity with the DecisionDx-Melanoma test had recurrence-free status after 3 years.

DecisionDx-Melanoma Test Accurately Identifies Low-Risk SLN Positivity

Roman Fabbricatore
April 4th 2025
Article

All patients identified as low risk for sentinel lymph node positivity with the DecisionDx-Melanoma test had recurrence-free status after 3 years.

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

Leticia Nogueira, PhD, MPH
March 31st 2025
Podcast

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

A futility analysis showed that ociperlimab was unlikely to reach the primary end point of overall survival as part of the phase 3 AdvanTIG-302 trial.

Developers Terminate Clinical Program for Ociperlimab in Lung Cancer

Russ Conroy
April 3rd 2025
Article

A futility analysis showed that ociperlimab was unlikely to reach the primary end point of overall survival as part of the phase 3 AdvanTIG-302 trial.

Data from the phase 3 CheckMate 77T trial support the CHMP’s opinion on approving the perioperative nivolumab regimen for those with resectable NSCLC.

EU’s CHMP Recommends Approving Perioperative Nivolumab Combo in NSCLC

Russ Conroy
April 2nd 2025
Article

Data from the phase 3 CheckMate 77T trial support the CHMP’s opinion on approving the perioperative nivolumab regimen for those with resectable NSCLC.